Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Terminal disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    684 result(s) found for: Terminal disease. Displaying page 4 of 35.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-004101-32 Sponsor Protocol Number: D4325C00001 Start Date*: 2021-04-06
    Sponsor Name:AstraZeneca
    Full Title: A Phase 2b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients w...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) BG (Completed) DK (Completed) IT (Completed) ES (Restarted) SK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002893-20 Sponsor Protocol Number: 2021/0188/HP Start Date*: 2021-12-03
    Sponsor Name:CHU de Rouen
    Full Title: Impact of dapagliflozin on vascular function in chronic kidney disease patients
    Medical condition: chronic kidney disease patients
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002329-23 Sponsor Protocol Number: SVCARB07609 Start Date*: 2013-06-20
    Sponsor Name:Genzyme Corporation and its Affiliates
    Full Title: A 2-Week, Randomized, Placebo-Controlled, Fixed Dose Period Followed by a 6-Month, Single-Arm, Open-Label, Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate ...
    Medical condition: Treatment of hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022011-19 Sponsor Protocol Number: PA-CL-05A Start Date*: 2011-02-21
    Sponsor Name:Vifor (International) Inc.
    Full Title: An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared with Sevelamer Carbonate Followed by a Randomised Co...
    Medical condition: Control of hyperphosphataemia in patients with chronic kidney disease on dialysis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    14.0 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) LV (Completed) LT (Completed) SE (Completed) AT (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022012-40 Sponsor Protocol Number: PA-CL-05B Start Date*: 2011-02-21
    Sponsor Name:Vifor (International) Inc.
    Full Title: An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 compared with Sevelamer Carbonate in D...
    Medical condition: Control of hyperphosphataemia in patients with chronic kidney disease on dialysis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    15.0 10027433 - Metabolism and nutrition disorders 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) LV (Completed) LT (Completed) SE (Completed) AT (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002786-35 Sponsor Protocol Number: CUA1 Start Date*: 2020-06-25
    Sponsor Name:Charlotte Uggerhøj Andersen
    Full Title: Pharmacokinetics and side effects for tetrahydrocannabinol and cannabidiol (Sativex) among patients with chronic kidney disease and patients on dialysis.
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-019243-19 Sponsor Protocol Number: 004-09 Start Date*: 2012-06-18
    Sponsor Name:Angion Biomedica Corp.
    Full Title: Pilot Study of BB3 to Improve Renal Function in Patients with Signs and Symptoms of Significant Renal Injury after Kidney Transplantation from Donors after Cardiac Death
    Medical condition: Patients suffering from end-stage renal disease, receiving a donor kidney from donors after cardiac death
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10014647 End stage renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005271-16 Sponsor Protocol Number: 2010NE02 Start Date*: 2012-11-29
    Sponsor Name:University of Dundee & NHS Tayside
    Full Title: Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis? A multicentre randomized placebo controlled trial
    Medical condition: Chronic kidney disease stages 4/5 with metabolic acidosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-004022-30 Sponsor Protocol Number: AKB-6548-CI-0041 Start Date*: 2022-03-02
    Sponsor Name:Akebia Therapeutics, Inc.
    Full Title: A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ONCE DAILY ORAL VADADUSTAT FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE AFTER CONVERSION FROM...
    Medical condition: Anemia of Chronic kidney disease (CKD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002272 Anemia LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Ongoing) FR (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003994-72 Sponsor Protocol Number: AKB-6548-CI-0042 Start Date*: 2022-03-02
    Sponsor Name:Akebia Therapeutics, Inc.
    Full Title: A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ONCE DAILY ORAL VADADUSTAT FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE NAÏVE TO ERYTHROPOIES...
    Medical condition: Anemia of Chronic kidney disease (CKD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002272 Anemia LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002721-99 Sponsor Protocol Number: CT114-2022-01 Start Date*: 2023-03-28
    Sponsor Name:Klinikum Nürnberg
    Full Title: Natriuretic-ureothelic adaptation of body fluid homeostasis during SGLT-2 inhibition and/or mineralocorticoid receptor modulation in patients with chronic kidney disease. A 4-arm, double-blind, dou...
    Medical condition: Stage 3 chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001824-36 Sponsor Protocol Number: 201201 Start Date*: 2012-07-12
    Sponsor Name:Medical University of Vienna, Department of Medicine III, Division of Nephrology und Dialysis
    Full Title: ORAL SODIUM BICARBONATE SUPPLEMENTATION IN PATIENTS WITH CHRONIC METABOLIC ACIDOSIS AND CHRONIC KIDNEY DISEASE
    Medical condition: Patients classified to have chronic kidney disease of stage 3 and 4 and chronic metabolic acidosis (venous serum HCO3- of <21mml/L on 2 separate measurements at least 1 day apart) should be include...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10027433 - Metabolism and nutrition disorders 10066569 Chronic acidosis LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008745-38 Sponsor Protocol Number: CKD-VitD-microcirc Start Date*: 2009-04-08
    Sponsor Name:Barts and the London NHS Trust
    Full Title: THE EFFECT OF VITAMIN D ON THE MICROCIRCULATION OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND VITAMIN D DEFICIENCY
    Medical condition: Chronic kidney disease and vitamin D deficiency.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047626 Vitamin D deficiency LLT
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001778-32 Sponsor Protocol Number: U1111-1149-7801 Start Date*: 2014-08-12
    Sponsor Name:Bo Feldt-Rasmussen
    Full Title: Glycaemic and cardiovascular efficacy of liraglutide in prediabetic patients with end-stage renal disease
    Medical condition: Prediabetes and dialysis dependent end-stage renal disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10014646 End stage renal disease (ESRD) LLT
    17.0 100000004861 10065542 Prediabetes LLT
    17.0 100000004869 10012347 Dependence on renal dialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001102-31 Sponsor Protocol Number: FG-506-02-41 Start Date*: 2005-07-08
    Sponsor Name:Astellas Pharma Europe Ltd
    Full Title: A phase II, open-label, multi-centre study to assess the effect of single and multiple oral doses (1 mg, 2 mg, and 3 mg) of everolimus on the pharmacokinetics of tacrolimus in stable renal transpla...
    Medical condition: Stable, adult kidney transplant recipients (≥ 6 months post transplant) who are currently treated with Prograf®/MMF(CellCept®) or Prograf®/Mycophenolate Sodium(Myfortic®) with or without steroids w...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10014646 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-023471-26 Sponsor Protocol Number: P-Monofer-CKD-03 Start Date*: 2011-09-08
    Sponsor Name:Pharmacosmos A/S
    Full Title: A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison with...
    Medical condition: Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD5D)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000773-23 Sponsor Protocol Number: I4M-MC-MRAC Start Date*: 2012-04-23
    Sponsor Name:Eli Lilly and Company
    Full Title: Study of the Safety and Efficacy of LY2623091 in Chronic Kidney Disease Patients
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015114-22 Sponsor Protocol Number: ML22916 Start Date*: 2010-08-10
    Sponsor Name:Roche Pharma AG
    Full Title: A randomized controlled, single-blind, proof- of- concept-study to investigate the protective effects of early treatment with C.E.R.A. in patients with chronic kidney disease on renal disease progr...
    Medical condition: diabetic and transplanted CKD stage III patients
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005345-36 Sponsor Protocol Number: D5610C00001 Start Date*: 2014-05-13
    Sponsor Name:Ardelyx, Inc.
    Full Title: An exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel design study to evaluate the safety, tolerability, and pharmacodynamics of AZD1722 in CKD patients with type 2 diabete...
    Medical condition: Chronic kidney disease (CKD) with type 2 diabetes mellitus and albuminuria
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004760-49 Sponsor Protocol Number: MK001 Start Date*: 2008-01-02
    Sponsor Name:University of Dundee
    Full Title: Do Xanthine Oxidase Inhibitors reduce both Left Ventricular Hypertrophy and Vascular Dysfunction in Cardiovascular patients with Renal Dysfunction?
    Medical condition: Chronic Kidney Disease Stage 3 Left Ventricular Hypertrophy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025164 LVH LLT
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 05:10:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA